soul trial oral semaglutide cardiovascular outcomes 2024 results nejm reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 πΈπͺ #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Michael Albert, MD on X:
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17
























